ORY-1001

Oryzon Genomics has been awarded €13.26 million through the Med4Cure initiative, a pan-European project focused on developing therapies for rare diseases with no current treatment options.

Oryzon Genomics has announced the dosing of the first patient in a Phase I trial of iadademstat for myelodysplastic syndrome (MDS).

Oryzon Genomics presented final Phase IIb PORTICO trial data for vafidemstat in Borderline Personality Disorder (BPD) at ECNP 2024, showing significant improvements in agitation and aggression.

Oryzon Genomics presented final Phase IIb PORTICO trial data for vafidemstat in Borderline Personality Disorder (BPD) at the ECNP conference, showing significant improvements in agitation and aggression.